

For Immediate Release

MedX[®] Health Corp Reports Third Quarter 2008 Financial Results

Mississauga, Ontario – November 10, 2008 - MedX Health Corp., a global leader in drug free, non-invasive low level laser and light therapy for tissue repair and pain relief, today announced its results for the three months ended September 30, 2008.

Revenue for the three months ended September 30, 2008 was \$335,567 compared to \$308,754 for the three months ended September 30, 2007, an 8.9 per cent increase. These revenues are also a 29.4% increase from revenues of \$259,235 for the second quarter of 2008.

MedX incurred a loss from continuing operations for the quarter of \$651,056 or \$0.03 per share compared to a loss of \$302,034 or \$0.02 per share for the same period in the prior year.

“For the first time in several years, MedX has posted a quarter to quarter increase from Q2 to Q3, 2008, as well as a quarter to quarter increase versus the previous period in 2007,” said Steven Guillen, chief executive officer and president of MedX Health. “This is a direct result of our Oralase™ laser gaining FDA clearance and our new strategic partnership, with Technology4Medicine, which is beginning to solidify and generate revenue. As we gain momentum in executing our business plan, we can expect to see a strong finish to the year and continue to expand our products and services internationally via new distribution channels, anticipated regulatory approval (CE Mark) in several countries, novel product technology, strategic partnerships and strong IP programs.”

Recent Company Achievements:

- Announced strategic partnership with Technology4Medicine to become Medx Health’s exclusive U.S. dental distributor for Oralase™ (July 15, 2008)
- Closed non-brokered private placement of 4,800,000 common shares for CAD\$1,200,000 (Q3, 2008)
- Company profiled in the October issue of *American Executive Magazine* (October 1, 2008)
- Received FDA Clearance for Oralase™ (October 6, 2008)

Canadian \$	Q3 2008	Q3 2007
Revenue	335,567	308,754
Gross Margin %	55%	70%
Income (Loss) from continued operations	(651,056)	(302,034)
Income (Loss) from discontinued operations	(8,290)	(5,763)
Net Income (Loss) for period	(659,346)	(307,797)
Weighted Average no. of shares outstanding-basic and diluted	22,222,776	15,043,937
Loss per Common Share-basic and diluted	(\$0.03)	(\$0.02)

About MedX Health Corp.

MedX is a leading North American developer and manufacturer of low level laser and light medical devices for the drug free and non-invasive treatment of tissue damage and pain in numerous medical settings including dental, rehabilitation and wound care. MedX is the world's only company focusing on developing and delivering a broad cross-section of technologies and products involved in healing using light therapy. MedX is committed to advocating for and bringing the non-invasive, drug-free healing nature of light to people seeking relief from pain and other physical ailments. MedX's strategy is to build upon its success in bringing relief of symptoms in a non-pharmacologic manner in the rehabilitation market through key partnerships, acquisitions, strong patent protection as well as developing and commercializing advanced products in the dental and wound-care markets that will position the company to increase revenue. In addition, MedX plans to accelerate the development of a new product aimed at the rapidly-growing wound care market: its "Photobandage™", a bandage technology that allows a wound to be bathed in light, designed to enhance the healing process. The Company intends to license this new technology to one or more major wound care companies for further development of marketing and sales.

Brand products are US FDA and Health Canada cleared and are produced in an ISO 9001 and 13485 certified manufacturing and testing facility. For a complete profile of MedX Health Corp. and its products visit www.medXhealth.com

For further information, please contact Steve Guillen, President & CEO, MedX Health Corp.
Telephone: 905.826.0766 Email: info@medxhealth.com

Investors:

Steve Guillen
President & CEO, MedX Health Corp.
Phone: (905) 826-0766
Email: guillen@medxhealth.com

Media:

Terri Clevenger
Continuum Health Communications
Phone (203) 227-0209
Email: tclevenger@continuumhealthcom.com

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release.

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Such forward-looking information may include statements regarding the Company's future plans, objectives, performance, growth, profits, operating expenses or its underlying assumptions. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "does not anticipate", or "believes" or variations

of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", or "will be taken", "occur", or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of MedX to be materially different from those expressed or implied by such forward-looking information, including uncertainty of successful development of new products, uncertainty of successful manufacturing or marketing of products, uncertainty of commercial acceptance of products, uncertainty concerning governmental regulation, dependency on key employees and relationships, rapid technological changes, foreign currency fluctuations. MedX does not undertake to update any forward-looking information, except in accordance with applicable securities laws.